Target Validation Information
TTD ID	T28661
Target Name	Tubulin beta-2 chain (TUBB2)
Type of Target	Successful
Drug Potency against Target	Vinblastine	Drug Info	Ki = 0.178+/-0.025 microM	[4]
	2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene	Drug Info	IC50 = 1600 nM	[3]
	2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene	Drug Info	IC50 = 1800 nM	[3]
	2-amino-3,4',5-trimethoxy-(Z)-stillbene	Drug Info	IC50 = 2400 nM	[3]
	3,4',5-trimethoxy-(Z)-stilbene	Drug Info	IC50 = 3500 nM	[3]
	3,4,4',5-tetramethoxy-(Z)-stilbene	Drug Info	IC50 = 1500 nM	[3]
	3-bromo-4,4',5-trimethoxy-(Z)-stilbene	Drug Info	IC50 = 2100 nM	[3]
	6-ile-ustiloxin	Drug Info	IC50 = 4800 nM	[1]
	DOLASTATIN-10	Drug Info	IC50 = 0.5 nM	[1]
	N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide	Drug Info	IC50 = 15700 nM	[2]
	USTILOXIN A	Drug Info	IC50 = 1100 nM	[1]
	Ustiloxin D	Drug Info	IC50 = 1500 nM	[1]
	Ustiloxin F	Drug Info	IC50 = 8200 nM	[1]
References
REF 1	Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
REF 2	Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70.
REF 3	2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
REF 4	Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 1985 Jun;45(6):2741-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.